Inventor · disambiguated record
Johannes Henricus Matthias Schellens
Also filed as: SCHELLENS JOHANNES HENRICUS · SCHELLENS JOHANNES HENRICUS M · SCHELLENS JOHANNES HENRICUS MA · SCHELLENS JOHANNES HENRICUS MATTHIAS
3 granted patents·10 pending applications·18 citations·filing 2001–2025
67Inventor score
Files withMODRA PHARMACEUTICALS B V4SLOTERVAART PARTICIPATIES BV2BEIJNEN JACOB HENDRIK1BYONDIS BV1CANCER RES VENTURES LTD1
Top patents by PatentIndex Score
13 records- 0184US11571408B2Cancer treatment using docetaxel by controlling peak plasma levelsMODRA PHARMACEUTICALS B V·Filed 2022·Granted Feb 7, 2023·2 cites·13 claims
- 0275US9089544B2CompositionBEIJNEN JACOB HENDRIK·Filed 2008·Granted Jul 28, 2015·2 cites·12 claims
- 0372US7030132B2Method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugsCANCER RES VENTURES LTD·Filed 2001·Granted Apr 18, 2006·14 cites·13 claims
- 0461US2022079910A1Cancer Treatment Useing Docetaxel by Controlling Peak Plasma LevelsMODRA PHARMACEUTICALS B V·Filed 2019·Application pending·0 cites
- 0560US2025312305A1Cancer Treatment Using Docetaxel by Controlling Peak Plasma LevelsMODRA PHARMACEUTICALS B V·Filed 2025·Application pending·0 cites
- 0651US2023092648A1Combination containing a duocarmycin derivative-comprising antibody-drug conjugate and thiosulfateBYONDIS BV·Filed 2021·Application pending·0 cites
- 0747US2022296637A1Sodium thiosulfate gel for preventing or reducing hearing lossSTICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS·Filed 2020·Application pending·0 cites
- 0845US2022071944A1Combination Treatment for Solid Tumors Using Docetaxel and a CYP3A InhibitorMODRA PHARMACEUTICALS B V·Filed 2019·Application pending·0 cites
- 0942US2011207804A1Compositions for the treatment of neoplastic diseasesSLOTERVAART PARTICIPATIES BV·Filed 2009·Application pending·0 cites
- 1042US2015328180A1CompositionSLOTERVAART PARTICIPATIES BV·Filed 2015·Application pending·0 cites
- 1139US2006128743A1Method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugsSCHELLENS JOHANNES HENRICUS M·Filed 2006·Application pending·0 cites
- 1235US2015198597A1Method for monitoring PARP activity in cells by PARP activationSTICHTING NL KANKER INST·Filed 2013·Application pending·0 cites
- 1329US2008312250A1Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -BenzamideNETHERLANDS CANCER INST·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →